Btk Kinase inhibitor Chemical Properties

Boiling point:

672.0±65.0 °C(Predicted)

Density 

1.412±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:65.0(Max Conc. mg/mL);143.02(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.66(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);66.01(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);2.2(Max Conc. mM)

form 

A crystalline solid

pka

3.16±0.20(Predicted)

color 

White to yellow

Btk Kinase inhibitor Usage And Synthesis

Description

Btk Kinase inhibitor is highly potent and selective orally administered, small molecule, and also named tirabrutinib, Brutons tyrosine kinase (BTK) inhibitor being developed by Ono pharmaceutical and its licensee Gilead Sciences for the treatment of autoimmune disorders and haematological malignancies. 

brand name

Velexbru^TM

Biological Functions

In March 2020, tirabrutinib was approved in  Japan to treat primary central nervous system lymphoma (PCNSL).  Tirabrutinib shows excellent selectivity against all kinases with cysteines in the ATP-binding site corresponding to Cys481 in BTK with the exception of BMX, TXK, and TEC? However, it displays weaker  BTK inhibition than ibrutinib (IC50 = 6.8 nM vs. 0.47  nM).

General Description

Class: non-receptor tyrosine kinase
Treatment: PCNSL
Elimination half-life = 6.5–8 h
Protein binding = 91%

Mechanism of action

The selective inhibition of cell growth by Btk Kinase inhibitor was due to blocking of BTK-mediated signaling through AKT and cellular protein kinase D. It can inhibit autophosphorylation of the BTK at the Tyr223 position through the ERK, AKT and PKD signaling pathways.

Side effects

Adverse effects of the Btk Kinase inhibitor that occurred in some patients were rash, vomiting, neutropenia, arthralgia, and malaise, and drug-related Grade 3–4 Adverse effects were neutropenia, leukopenia, anemia, hypophosphatemia, PT-INR increased, pneumonitis, and acute myeloid leukemia. in prior Japanese studies, rash, hematologic adverse effects, erythema multiforme, and constipation were frequent adverse effects in a Phase I/II study of some patients with PCNSL, and rash, hematologic adverse effects, and stomatitis were the most common adverse effects in a Phase II study of some patients with WM.

target

BTK

Btk Kinase inhibitor(1351636-18-4)Related Product Information

• ONO-4059 (hydrochloride)
• Flumatinib
• Afatinib (BIBW 2992)